Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic liver diseases. However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose ...

In patients with chronic liver disease, including PBC, ursodeoxycholic acid shows promise as an adjunctive therapy for COVID-19 infection.

Report with the AI impact on market trends- The global ursodeoxycholic acid market size is estimated to grow by USD ...

In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

ASTANA – From fresh milk to its fermented state and finally as a sublimated powder, scientists reveal why mare’s milk should ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH. Methods: Western and Chinese databases were ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

Discover all the brand names or Trade names of generic drug called Ursodeoxycholic Acid. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking ...

Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine.

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...